TipRanks on MSN

C4 Therapeutics Presents Phase 1 Trial Data

An announcement from C4 Therapeutics ( ($CCCC) ) is now available. On October 16, 2025, C4 Therapeutics announced the presentation of data from ...
Nasdaq

C4 Therapeutics Reports Promising Cemsidomide Data in Multiple Myeloma and Announces Strategic Development Priorities

C4 Therapeutics, Inc. (C4T) announced promising results from the latest data on its investigational drug cemsidomide for treating multiple myeloma, showing a 50% overall response rate (ORR) at the ...
TipRanks on MSN

C4 Therapeutics Announces Stock and Warrants Offering

C4 Therapeutics ( ($CCCC) ) has shared an update. On October 16, 2025, C4 Therapeutics announced an underwritten offering of common stock and ...
Taiwan News

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed ...

The Phase 1b trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for patients with ...